A Phase I Study of MLN9708 and Vorinostat to Target Autophagy in Patients With Advanced p53 Mutant Malignancies
Latest Information Update: 12 Jul 2022
At a glance
- Drugs Ixazomib (Primary) ; Vorinostat (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 08 Jul 2022 Status changed from active, no longer recruiting to completed.
- 29 Jun 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.
- 29 Jun 2022 Planned primary completion date changed from 1 Jun 2021 to 1 Jun 2023.